Claims for Patent: 7,220,767
✉ Email this page to a colleague
Summary for Patent: 7,220,767
| Title: | Pharmaceutical formulations containing zolmitriptan |
| Abstract: | A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders. |
| Inventor(s): | Dearn; Alan Roy (Hertfordshire, GB), Williamson; Sarah Louise (Hertfordshire, GB), Summers; John Simon (Hertfordshire, GB), Coomber; Trevor John (Hertfordshire, GB) |
| Assignee: | AstraZeneca AB (Sodertalje, SE) |
| Application Number: | 10/854,959 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,220,767 |
| Patent Claims: |
1. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the
formulation is less than 6.0.
2. A pharmaceutical formulation according to claim 1 wherein the pH of the formulation is in the range 3.5 to 5.5. 3. A pharmaceutical formulation according to claim 1 wherein the formulation is buffered. 4. A pharmaceutical formulation according to claim 2 wherein the formulation is buffered. 5. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is less than 6.0, wherein the formulation is buffered by a mixture of citric acid and disodium phosphate. 6. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is in the range 3.5 to 5.5, wherein the formulation is buffered by a mixture of citric acid and disodium phosphate. 7. A pharmaceutical formulation according to claim 1 which is sterile. 8. A pharmaceutical formulation according to claim 2 which is sterile. 9. A pharmaceutical formulation according to claim 3 which is sterile. 10. A pharmaceutical formulation according to claim 4 which is sterile. 11. A pharmaceutical formulation according to claim 5 which is sterile. 12. A pharmaceutical formulation according to claim 6 which is sterile. 13. An intranasal administration device containing a pharmaceutical formulation as defined in any one of claims 1, 2, 6 or 7. 14. An intranasal administration device containing a pharmaceutical formulation as defined in any one of claims 1 to 12 when packaged to provide protection from light. 15. An aqueous solution of zolmitriptan in a buffer at a pH of less than 6.0. 16. The aqueous solution of claim 15, wherein the pH is in the range 3.5 to 5.5. |
